Ascelia Pharma

2.93 SEK

-1.68 %

Less than 1K followers

ACE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

-1.68 %
+0.86 %
+6.17 %
-9.02 %
-3.15 %
-22.62 %
-71.39 %
-88.27 %
-83.00 %

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital. Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Read more
Market cap
393.62M SEK
Turnover
1.39M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Coverage
Disclaimer
Michael Friis
Philip Coombes
Philip Coombes, Michael Friis
Show more
Latest research

Latest analysis report

Released: 10.02.2026

Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.5
2026

Interim report Q1'26

20.8
2026

Interim report Q2'26

5.11
2026

Interim report Q3'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Ascelia Pharma – Presentation of Q1 2026 results
Webcast

Ascelia Pharma – Presentation of Q1 2026 results

Ascelia Pharma is expected to release its Q1 2026 results on 12 May 2026. The following day at 11:00, CEO Magnus Corfitzen will present the results and provide an update on the company's latest developments in a live online event. The Q1 presentation arrives at a pivotal moment for Ascelia Pharma, with the FDA PDUFA decision date for Orviglance set for 3 July 2026 , and ongoing partnership discussions.

Ascelia Pharma
Ascelia Pharma (One pager): Counting down to two high-value catalysts in 2026
Research by
Philip Coombes, Michael Friis

Ascelia Pharma (One pager): Counting down to two high-value catalysts in 2026

We have only made minor adjustments to our Ascelia Pharma one-pager following the FY 2025 results. The FDA timeline for Orviglance was already known ahead of the report, with the NDA accepted for review in November 2025 and a PDUFA decision date confirmed for 3 July 2026. The FY 2025 results, therefore, contained no major surprises, and our investment case remains largely unchanged with only minor adjustments. Notably, management expressed increased confidence on partnering in connection with the report. CEO Magnus Corfitzen stated that the partnering process continues to progress, with multiple potential partners demonstrating strong strategic interest.

Ascelia Pharma
Ascelia Pharma: Video presentation of the 2025 results
Analyst Comment by
Michael Friis

Ascelia Pharma: Video presentation of the 2025 results

Today, we hosted an event with Magnus Corfitzen, CEO of Ascelia Pharma. The presentation focused on the financial results and regulatory milestones achieved during the fourth quarter, with particular emphasis on the investment case for Orviglance. The event concluded with a Q&A session, with discussion centred on the status and outlook regarding potential partners.

Ascelia Pharma
Ascelia Pharma – Presentation of FY 2025 results
Webcast

Ascelia Pharma – Presentation of FY 2025 results

Ascelia Pharma is expected to release its full-year 2025 results on 5 February 2026. Join us for a live presentation with CEO Magnus Corfitzen from Ascelia Pharma the following day at 13:00, where he will present the financial results for 2025 and provide an update on the company’s latest developments.

Ascelia Pharma
Forum discussions
Let’s open a thread for this one too. Ascelia is a company from Sweden specializing in cancer diagnostics and treatment. Company page: Ascelia Pharma - Inderes Investment research: https://www.inderes.fi/fi/ascelia-pharma-investment-case-24-march-2022-hc-andersen-capital
5/4/2022, 3:32 PM
by Yu Gong
11
It has been on my watchlist. The stock crashed a few years ago when two graders had interpreted the same MRI images differently at different points in time. The interpretations had to be redone. The company got into a difficult spiral with financing during the post-covid crash. This...
2/20/2026, 3:16 PM
by Clark kent
1
Like many other companies in the biotech sector, Ascelia has experienced total capitulation in its share price. However, it should be noted that FDA approval is just around the corner, and even though it is a penny stock, that does not in itself dictate the future. Fundamentally,...
2/13/2026, 10:37 AM
by Hawkmountdiver
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.